Ahead of the FDA’s decision on Bristol Myers Squibb’s schizophrenia treatment KarXT, the Big Pharma has kicked off a campaign this week to improve education around and destigmatize the mental illness while also providing helpful resources for patients.
Terran Biosciences Announces Development of TerXT, a Combination of Xanomeline and Trospium Prodrugs for the Treatment of Schizophrenia, and Intends to Pursue Accelerated 505(b)(2) Approval Pathway
An experimental drug from Karuna Therapeutics has succeeded in a second late-stage clinical trial testing it as a potential therapy for schizophrenia.
MIAMI--(BUSINESS WIRE)--Segal Trials, a privately held network of clinical research sites throughout South Florida has concluded a phase 3 EMERGENT-2 trial with Karuna Therapeutics. The study focused on evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The study was overseen by Segal Trials, Chief Scientific Officer, & Principal Investigator, Rishi Kakar, MD.
Karuna announces positive results from Phase III trial into schizophrenia
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner, Karuna Therapeutics, Inc. (NASDAQ: KRTX), reported positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo, p<0.0001) at Week 5 (Cohen’s d effect size of 0.61). KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained such reduction through all timepoints in the trial.
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2022 and provided a general business update.
Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. It is trading on the Nasdaq under the ticker symbol KRTX. On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.
Boston-based Karuna Pharmaceuticals originally filed for its IPO in April and began trading today. It is trading on the Nasdaq under the ticker symbol KRTX. On June 17, it set its pricing between $15 and $17 per share to raise $74.4 million.
Less than a year after raising $42 million, banking on the potential of two older drugs as an approach to fight Alzheimer’s and schizophrenia, Boston-based Karuna Pharmaceuticals on Friday laid the groundwork for a $75 million IPO.